Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Sung AD, Koll T, Gier SH, Racioppi A, White G, Lew M, Free M, Agarwal P, Bohannon LM, Johnson EJ, Selvan B, Babushok DV, Frey NV, Gill SI, Hexner EO, Martin M, Perl AE, Pratz KW, Luger SM, Chao NJ, Fisher AL, Stadtmauer EA, Porter DL, Loren AW, Bhatt VR, Gimotty PA, McCurdy SR. Sung AD, et al. Among authors: hexner eo. Transplant Cell Ther. 2024 Apr;30(4):415.e1-415.e16. doi: 10.1016/j.jtct.2024.01.062. Epub 2024 Jan 17. Transplant Cell Ther. 2024. PMID: 38242440
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, Sun W, Gopalakrishna P, Kantarjian H, Verstovsek S. Gupta V, et al. Among authors: hexner eo. Haematologica. 2016 Dec;101(12):e482-e484. doi: 10.3324/haematol.2016.151449. Epub 2016 Sep 1. Haematologica. 2016. PMID: 27587385 Free PMC article. Clinical Trial. No abstract available.
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Hexner EO, Mascarenhas J, Prchal J, Roboz GJ, Baer MR, Ritchie EK, Leibowitz D, Demakos EP, Miller C, Siuty J, Kleczko J, Price L, Jeschke G, Weinberg R, Basu T, Pahl HL, Orazi A, Najfeld V, Marchioli R, Goldberg JD, Silverman LR, Hoffman R. Hexner EO, et al. Leuk Lymphoma. 2015;56(9):2543-51. doi: 10.3109/10428194.2014.1001986. Epub 2015 Feb 20. Leuk Lymphoma. 2015. PMID: 25563429 Free PMC article. Clinical Trial.
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL. Hartwell MJ, et al. Among authors: hexner eo. JCI Insight. 2018 Aug 23;3(16):e124015. doi: 10.1172/jci.insight.124015. eCollection 2018 Aug 23. JCI Insight. 2018. PMID: 30135313 Free PMC article. No abstract available.
Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation.
Hexner EO, Danet-Desnoyers GA, Zhang Y, Frank DM, Riley JL, Levine BL, Porter DL, June CH, Emerson SG. Hexner EO, et al. Biol Blood Marrow Transplant. 2007 Oct;13(10):1135-44. doi: 10.1016/j.bbmt.2007.06.010. Biol Blood Marrow Transplant. 2007. PMID: 17889349 Free article.
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM. Perl AE, et al. Among authors: hexner eo. Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20. Clin Cancer Res. 2009. PMID: 19843663 Clinical Trial.
102 results